Adalimumab

Mucopolysaccharidosis Type VI

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Centermonoclonal_antibodyPhase 1/2Active

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

3 Active assets in the Mucopolysaccharidosis Type VI cohort.

Asset / Sponsor	Phase	Rating
GALSULFASE Masonic Cancer Center, University of Minnesota	Phase 4	B
GALSULFASE BioMarin Pharmaceutical	Phase 4	B
Cyclophosphamide Masonic Cancer Center, University of Minnesota	Phase 2	B
Busulphan Masonic Cancer Center, University of Minnesota	Phase 2	B
Genotropin Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 2/3	B